A subcutaneous bispecific T-cell–engaging monoclonal antibody that binds BCMA (TNFRSF17) on malignant plasma cells and CD3 on T cells to activate T-cell receptor/CD3 signaling, induce cytotoxic T-cell killing, and trigger apoptosis of BCMA-positive plasma cells.
Bispecific monoclonal antibody that binds BCMA on malignant plasma cells and CD3 on T cells, crosslinking them to activate T-cell receptor/CD3 signaling, drive cytotoxic T-cell killing, and induce apoptosis of BCMA-positive plasma cells.
YES
DIRECT
Elranatamab bridges CD3 on T cells to BCMA on target cells, activating T cells to deliver perforin/granzymes and induce apoptosis of BCMA-positive cells.
A subcutaneous bispecific T-cell–engaging monoclonal antibody that binds BCMA (TNFRSF17) on malignant plasma cells and CD3 on T cells to activate T-cell receptor/CD3 signaling, induce cytotoxic T-cell killing, and trigger apoptosis of BCMA-positive plasma cells.
Bispecific monoclonal antibody that binds BCMA on malignant plasma cells and CD3 on T cells, crosslinking them to activate T-cell receptor/CD3 signaling, drive cytotoxic T-cell killing, and induce apoptosis of BCMA-positive plasma cells.
NO
INDIRECT
Elranatamab engages CD3 on T cells to activate them and crosslink to BCMA on tumor cells; activated T cells kill BCMA-positive cells via perforin/granzyme-mediated apoptosis. CD3+ T cells are not directly killed.
Bispecific T-cell engager (BiTE) antibody construct that binds CD19 on B-cell blasts and CD3 on T cells, redirecting T-cell cytotoxicity to eliminate CD19+ leukemia and minimal residual disease.
CD19xCD3 bispecific (BiTE) antibody that simultaneously binds CD19 on B cells and CD3 on T cells, recruiting and activating T cells to form an immunologic synapse and mediate perforin/granzyme-dependent lysis of CD19-positive leukemia cells, independent of MHC.
YES
DIRECT
Blinatumomab links CD3 on T cells to CD19 on target cells, inducing an immunologic synapse and T‑cell activation that kills CD19+ cells via perforin/granzyme-dependent cytolysis (MHC-independent).
Bispecific T-cell engager (BiTE) antibody construct that binds CD19 on B-cell blasts and CD3 on T cells, redirecting T-cell cytotoxicity to eliminate CD19+ leukemia and minimal residual disease.
CD19xCD3 bispecific (BiTE) antibody that simultaneously binds CD19 on B cells and CD3 on T cells, recruiting and activating T cells to form an immunologic synapse and mediate perforin/granzyme-dependent lysis of CD19-positive leukemia cells, independent of MHC.
NO
INDIRECT
Blinatumomab binds CD3ε on T cells to recruit/activate them against CD19+ cells; the T cells then kill CD19-expressing targets via perforin/granzyme, not the CD3+ T cells.
Anti-CD2 monoclonal antibody biologic that binds CD2 on T cells and NK cells, blocks CD2–CD58 costimulatory signaling, and preferentially depletes/modulates memory T cells to reduce alloimmune and autoimmune activity after liver transplant.
Humanized IgG1 monoclonal antibody against CD2 that binds T and NK cells, blocks CD2–CD58 costimulatory signaling, and depletes/modulates CD2+ (especially memory) T cells via immune effector mechanisms (e.g., ADCC/CDC), suppressing alloimmune and autoimmune activity.
YES
DIRECT
Anti-CD2 IgG1 binds CD2 on T/NK cells and its Fc engages effector pathways (ADCC via FcγR-bearing cells and complement-dependent cytotoxicity), leading to lysis/depletion of CD2+ cells.